RxDoctor Payments Data

Manoranjan Muthukanagaraj, MD

Psychiatry · Washington, NCNPI 1750765244

Payments from drug & device makers

$3,190in general payments, 2019–2025

Across 162 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$580
  • Otsuka America Pharmaceutical, Inc.$450
  • Alkermes, Inc.$406
  • Johnson & Johnson$321
  • Lundbeck LLC$266
  • Neurocrine Biosciences, Inc.$251
  • plus $916 from 9 others

What the payments were for

  • Food & beverage$3,190100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,190 in reported general payments places this provider in the 80th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$36,032
Medicare patients
103
Services billed
384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate45$377,281
Invega SustennaPaliperidone Palmitate68$226,129
AustedoDeutetrabenazine15$118,004
RexultiBrexpiprazole52$80,134
VraylarCariprazine Hcl52$76,175
CaplytaLumateperone Tosylate11$21,277
Chlorpromazine Hcl16$10,732
TrintellixVortioxetine Hydrobromide19$9,405
Aripiprazole175$7,399
Desvenlafaxine Succinate ErDesvenlafaxine Succinate36$6,809
BelsomraSuvorexant13$5,746
Paliperidone ErPaliperidone28$3,487
Quetiapine Fumarate ErQuetiapine Fumarate39$3,207
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine54$3,142
Mirtazapine250$3,141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$251$377,28145 claims
Johnson & JohnsonInvega Sustenna$321$226,12968 claims
Teva Pharmaceuticals USA, Inc.Austedo$199$118,00415 claims
Otsuka America Pharmaceutical, Inc.Rexulti$450$80,13452 claims
AbbVieVraylar$580$76,17552 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$195$21,27711 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$169$9,40519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Washington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →